NCT01366144 2026-04-13
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
National Cancer Institute (NCI)
Phase 1 Active not recruiting
Clinical Trials
125 trialsNCT04540211 2026-04-09
SKYSCRAPER-08
Hoffmann-La Roche
Phase 3 Completed
NCT06445972 2026-04-02
MK-3475-06D
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT03044613 2026-03-23
Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Active not recruiting
NCT05319730 2026-03-20
MK-3475-06B
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT02359968 2026-03-18
PROTECT
Centre Oscar Lambret
Phase 2 Completed
NCT05183126 2026-03-06
Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer
University of Michigan Rogel Cancer Center
Phase 4 Recruiting
NCT06047379 2026-03-02
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
Phase 1/2 Recruiting
NCT01196390 2026-02-18
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT02213497 2026-01-08
Dose Escalation of Neoadjuvant Proton Beam Radiotherapy With Concurrent Chemotherapy in Locally Advanced Esophageal Cancer
Abramson Cancer Center at Penn Medicine
Phase 1 Active not recruiting
NCT05342636 2025-12-17
A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)
Merck Sharp & Dohme LLC
Phase 1/2 Completed
NCT02297217 2025-12-16
PaRCUS
AHS Cancer Control Alberta
Phase 2 Recruiting
NCT03281369 2025-12-15
A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)
Hoffmann-La Roche
Phase 1/2 Completed
NCT06914011 2025-12-03
MRD2START
Asan Medical Center
Phase 3 Not yet recruiting
NCT06251973 2025-12-02
A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT01142388 2025-11-25
Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06143748 2025-09-17
EC-CRT-006
Sun Yat-sen University
Phase 2 Active not recruiting
NCT03110926 2025-09-12
Induction Chemotherapy for Locally Advanced Esophageal Cancer
University of Rochester
Phase 2 Active not recruiting
NCT05007106 2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT02013154 2025-08-03
P102
Leap Therapeutics, Inc.
Phase 1 Completed
NCT04046575 2025-07-11
Radiation Dose Intensification With Accelerated Hypofractionated Intensity Modulated Radiation Therapy and Concurrent Carboplatin and Paclitaxel for Inoperable Esophageal Cancer
Washington University School of Medicine
Phase 1 Active not recruiting
NCT05357846 2025-06-12
PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)
Sun Yat-sen University
Phase 3 Recruiting
NCT06965829 2025-05-11
The Effect of Neoadjuvant Chemoimmnotherapy Combined With Node Sparing Radiotherapy for cT3N+ EC
Shanghai Chest Hospital
Phase 2 Not yet recruiting
NCT06914687 2025-04-06
Efficacy of Tirellizumab Combined With Oral, Intravenous and Abdominal Chemotherapy in Peritoneal Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma
Fudan University
Phase 2 Not yet recruiting
NCT05191667 2025-02-13
AN0025 and Chemoradiotherapy Combination in Esophageal Cancer
Adlai Nortye Biopharma Co., Ltd.
Phase 1 Suspended
NCT05628610 2024-08-13
Tislelizumab Combined With Chemotherapy or Radiotherapy in the Treatment of Advanced or Recurrent Metastatic Elderly Esophageal Cancer
Fujian Cancer Hospital
Phase 2 Not yet recruiting
NCT04481256 2024-07-26
TAPESTRY
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase NA Recruiting
NCT06084897 2024-06-14
Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT05395910 2024-05-29
Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) and Electrostatic PIPAC (ePIPAC) With Paclitaxel In Patients With Peritoneal Carcinomatosis
National University Hospital, Singapore
Phase 1 Recruiting
NCT05490719 2024-05-21
A Phase II Study of CRT Combined With QL1706 in ESCC Patients
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Recruiting
NCT02509286 2024-05-08
ESOPEC
University Hospital Schleswig-Holstein
Phase 3 Active not recruiting
NCT03165994 2024-05-02
APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers
Apexigen America, Inc.
Phase 2 Completed
NCT02735239 2024-03-22
Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer
Ludwig Institute for Cancer Research
Phase 1/2 Completed
NCT02735057 2024-01-18
OSAGE
Centre Hospitalier Universitaire de Besancon
Phase 1/2 Recruiting
NCT02037048 2024-01-08
FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma
Case Comprehensive Cancer Center
Phase 2 Unknown
NCT02988921 2023-11-24
MRI and CT Simulation in the Evaluation of Tumor Response and Target Volume Definition for Esophageal or Esophagogastric Cancer Patients Undergoing Chemoradiotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase NA Recruiting
NCT01522768 2023-11-01
Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT03748134 2023-10-24
Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 )
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3 Completed
NCT05996484 2023-08-21
Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal Carcinoma
Nanfang Hospital, Southern Medical University
Phase 2 Not yet recruiting
NCT04764227 2023-08-03
Phase II Study of Postoperative Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ESO- Shanghai 17)
Fudan University
Phase 2 Active not recruiting
NCT05281003 2023-07-13
HYPERION
Fudan University
Phase 2 Recruiting
NCT00033657 2023-06-28
Radiation Therapy and Chemotherapy Before and After Surgery in Treating Patients With Esophageal Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00003237 2023-06-22
Combination Chemotherapy After Surgery in Treating Patients With Cancer of the Esophagus or Stomach
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT03094884 2023-05-23
Pulsed Low Dose Rate Radiation With Concurrent Chemotherapy for Non-Small Cell Lung Cancer and Esophageal Cancer
Fox Chase Cancer Center
Phase 1 Unknown
NCT01333033 2023-04-13
PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT03933449 2023-03-29
KEYNOTE-181
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03544736 2023-03-22
Safety and Feasibility of Irradiation and Nivolumab in Esophageal Cancer (INEC)
Oslo University Hospital
Phase 1/2 Active not recruiting
NCT02564263 2023-03-13
KEYNOTE-181
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT05637268 2022-12-05
Carrelizumab Combined With Chemotherapy for Adjuvant Therapy of Esophageal Squamous Cell Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT05245760 2022-11-08
CRATER
University of Kentucky
Phase 2 Withdrawn